<DOC>
	<DOC>NCT02485600</DOC>
	<brief_summary>This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).</brief_summary>
	<brief_title>Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa, levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Diagnosed with advanced Parkinson's Disease Prescribed Duodopa by his/her treating physician. Patients who were previously treated with Duodopa. Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of advanced PD.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>LCIG</keyword>
	<keyword>Duodopa</keyword>
	<keyword>Parkinson's disease</keyword>
	<keyword>Observational</keyword>
	<keyword>Cadence</keyword>
	<keyword>Levodopa-carbidopa intestinal gel</keyword>
</DOC>